TABLE 2-1

Study

Country

Study Typea

Study Population

Women's Antioxidant Cardiovascular Study (Manson et al., 1995)

U.S.

Secondary prevention; randomized, double-blind, placebo-controlled intervention

8,000 women with prior CVD event or ≥3 coronary risk factors, aged ≥40 y

Women's Health Study (Buring and Hennekens, 1992)

U.S.

Primary prevention; randomized, double-blind, placebo-controlled intervention

39,876 healthy women, aged ≥45 y

Physician's Health Study II (Hennekens, 1998)

U.S.

Primary prevention; randomized, double-blind, placebo-controlled intervention

15,000 healthy male physicians, aged ≥55 y

SUVIMAX (Hercberg et al., 1998)

France

Primary prevention; randomized, double-blind, placebo-controlled intervention

12,735 men and women, aged 35–60 y

a A primary prevention trial is one in which the study participants have no history of the disease outcome being investigated. Participants in a secondary prevention trial have had a prior occurrence of the outcome being investigated.

b Unless noted otherwise, results are statistically significant.

c U.S. = United States.

d CVD = cardiovascular disease.

task was to select, in addition to vitamin C, vitamin E, and β-carotene, other food components which might prove to be antioxidants and play a role in health; the third task was to assess the role of these compounds in health; and the fourth task was to develop Dietary Reference Intakes (DRIs) for the selected nutrients. The panel was asked to evaluate vitamin C, vitamin E, and β-carotene and other antioxidants. Since other dietary carotenoids share many,



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement